Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.46 |
| ▸ | BACE1 | P56817 | 3/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.39 |
| ▸ | AXL | P30530 | 1/20 | 0.38 |
| ▸ | MERTK | Q12866 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | DRD4 | P21917 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HTR5A | P47898 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14223080 | 0.90 | ACHE (0.48) | ACHEBACE1BCHEHRH3MEN1 | |
| SCHEMBL2802000 | 0.88 | TEAD1 (0.53) | ACHEBACE1BCHETEAD1MCHR1 | |
| SCHEMBL2806279 | 0.86 | BCHE (0.52) | ACHEBACE1BCHEHRH3TEAD1 | |
| SCHEMBL14216185 | 0.86 | ACHE (0.45) | ACHEBACE1BCHEHRH3MEN1 | |
| SCHEMBL13159621 | 0.79 | ACHE (0.45) | ACHEBACE1BCHEHRH3AKT1 | |
| SCHEMBL3631495 | 0.78 | TEAD1 (0.52) | ACHEBACE1BCHETEAD1DRD4 | |
| SCHEMBL2804476 | 0.78 | TEAD1 (0.56) | ACHEBACE1BCHEHRH3TEAD1 | |
| SCHEMBL3797015 | 0.76 | BCHE (0.54) | ACHEBACE1BCHEHRH3MEN1 | |
| SCHEMBL2802531 | 0.76 | TEAD1 (0.54) | ACHEBACE1BCHEHRH3TEAD1 | |
| SCHEMBL14223527 | 0.74 | SLC6A3 (0.39) | HRH3MEN1RAB9AKMT2ATEAD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130150379-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2013-06-13 | — | — | US | disclosed |
| US-7705005-B2 | Bicyclic heteroaromatic compounds | GLAXO GROUP LIMITED (GB) | 2010-04-27 | — | — | US | disclosed |
| WO-2008140449-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | THOMAS JEFFERSON UNIVERSITY (US) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008140450-A1 | METHODS OF TREATMENT AND PREVENTION OF METABOLIC BONE DISEASES AND DISORDERS | THOMAS JEFFERSON UNIVERSITY (US) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008141176-A1 | METHODS OF TREATMENT OF SKIN ULCERS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2008-11-20 | — | — | WO | disclosed |
| US-20080280829-A1 | METHODS OF TREATMENT AND PREVENTION OF METABOLIC BONE DISEASES AND DISORDERS | THOMAS JEFFERSON UNIVERSITY (US) | 2008-11-13 | — | — | US | disclosed |
| US-20080103156-A1 | Bicyclic Heteroaromatic Compounds | GLAXO GROUP LIMITED (GB) | 2008-05-01 | — | — | US | disclosed |
| WO-2008048867-A2 | BICYCLIC HETEROAROMATIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008048866-A2 | BICYCLIC HETEROAROMATIC COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-04-24 | — | — | WO | disclosed |
| US-20080090851-A1 | Bicyclic Heteroaromatic Compounds | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
| US-20080090853-A1 | Bicyclic Heteroaromatic Compounds | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
| US-20080090852-A1 | Bicyclic Heteroaromatic Compounds | GLAXO GROUP LIMITED (GB) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280829-A1 | METHODS OF TREATMENT AND PREVENTION OF METABOLIC BONE DISEASES AND DISORDERS | ENPP2, PLA2G12A, PLA2G12B | ACHE 753/4885BACE1 1484/4885BCHE 624/4885 |
| US-20080090851-A1 | Bicyclic Heteroaromatic Compounds | CYP11B1, CYP46A1, CYP11B2 | ACHE 3983/4885BACE1 280/4885BCHE 2441/4885 |
| US-20080090852-A1 | Bicyclic Heteroaromatic Compounds | CYP11B1, CYP46A1, CYP11B2 | ACHE 4187/4885BACE1 275/4885BCHE 2544/4885 |
| US-20130150379-A1 | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS | LPL, PLA2G1B, PLA2G2A | ACHE 34/4885BACE1 74/4885BCHE 76/4885 |
| US-20080090853-A1 | Bicyclic Heteroaromatic Compounds | GPR6, CNR1, NR3C1 | ACHE 4476/4885BACE1 3869/4885BCHE 2596/4885 |
| US-20080103156-A1 | Bicyclic Heteroaromatic Compounds | CYP11B1, CYP46A1, CYP11B2 | ACHE 3983/4885BACE1 280/4885BCHE 2441/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.